Literature DB >> 21455689

Cancer: a proteomic disease.

GuoQing Li1, ZheFeng Xiao, JianPing Liu, Cui Li, Feng Li, ZhuChu Chen.   

Abstract

The development of cancer is a pathological process involving multiple environmental carcinogenic factors and genetic alterations. For decades, cancer researchers have focused on genomic and transcriptomic analyses. The completion of the Human Genome Project has opened the door to the post-genome era and oncoproteomics. Proteins play a critical role in tumorigenesis and influence the differences between normal cells and malignant cells. This report proposes the concept that cancer is a proteomic disease. This concept is based on examining protein expression profiles, post-translational modifications, and protein-protein interactions in carcinogenesis using recent advances in comparative, functional and structural proteomics. This approach provides a new way of viewing carcinogenesis, presents new clues in biomarker discovery for cancer diagnosis and therapy, and reveals important scientific findings and their significance to clinical applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455689     DOI: 10.1007/s11427-011-4163-0

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  9 in total

1.  Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro.

Authors:  Ze-Ya Pan; Yun Yang; Hao Pan; Jin Zhang; Hui Liu; Yuan Yang; Gang Huang; Lei Yin; Jian Huang; Wei-Ping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines.

Authors:  Ogunc Meral; Hamdi Uysal
Journal:  Tumour Biol       Date:  2014-10-01

Review 3.  The Potential of Targeting P53 and HSP90 Overcoming Acquired MAPKi-Resistant Melanoma.

Authors:  Chi-Che Hsieh; Che-Hung Shen
Journal:  Curr Treat Options Oncol       Date:  2019-02-18

Review 4.  Research status and funding trends of lung cancer biomarkers.

Authors:  Cui Li; Wei Hong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

5.  Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway.

Authors:  V Medina Villaamil; G Aparicio Gallego; M Valladares-Ayerbes; I Santamarina Caínzos; L Miguel Antón Aparicio
Journal:  J Mol Signal       Date:  2012-09-01

6.  Label-Free Proteome Analysis of Plasma from Patients with Breast Cancer: Stage-Specific Protein Expression.

Authors:  Marina Duarte Pinto Lobo; Frederico Bruno Mendes Batista Moreno; Gustavo Henrique Martins Ferreira Souza; Sara Maria Moreira Lima Verde; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Front Oncol       Date:  2017-02-02       Impact factor: 6.244

7.  Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma.

Authors:  Fei-Yi-Fan Wang; Si-Yi Wang-Gou; Hang Cao; Nian Jiang; Qi Yang; Qi Huang; Chun-Hai Huang; Xue-Jun Li
Journal:  Cancer Commun (Lond)       Date:  2020-09-04

8.  Coupling of Cell Surface Biotinylation and SILAC-Based Quantitative Proteomics Identified Myoferlin as a Potential Therapeutic Target for Nasopharyngeal Carcinoma Metastasis.

Authors:  Maoyu Li; Fang Peng; Guoqiang Wang; Xujun Liang; Meiying Shao; Zhuchu Chen; Yongheng Chen
Journal:  Front Cell Dev Biol       Date:  2021-06-09

9.  Comparison of Helicobacter bilis-Associated Protein Expression in Huh7 Cells Harbouring HCV Replicon and in Replicon-Cured Cells.

Authors:  Arinze S Okoli; Mark J Raftery; George L Mendz
Journal:  Int J Hepatol       Date:  2012-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.